Frequent occurrence of oxacillin-susceptible mecA-positive Staphylococcus aureus (OS-MRSA) strains in two African countries

The Journal of Antimicrobial Chemotherapy
T ConceiçãoM Aires-de-Sousa

Abstract

Oxacillin-susceptible mecA-positive Staphylococcus aureus (OS-MRSA) isolates have been increasingly reported worldwide, but data regarding the African continent have not been available. Between 2010 and 2014, 1462 inpatients and healthcare workers were screened for MRSA nasal carriage in São Tomé and Príncipe (STP) and Angola, two Portuguese-speaking African countries (PALOP countries). We determined the presence of the mecA gene and the antimicrobial susceptibility profiles of the isolates. OS-MRSA clonal lineages were identified as well as the presence of virulence determinants, including Panton-Valentine leucocidin (PVL). Out of 164 S. aureus hospital isolates tested, 29 (17.7%) were mecA positive, but susceptible to oxacillin, showing oxacillin MICs ≤3 mg/L. All OS-MRSA isolates were resistant to cefoxitin and most of them were also resistant to at least two antimicrobials other than β-lactams. The 29 OS-MRSA were distributed into two major clonal lineages: (i) PFGE type B-ST88-SCCmec IVa, associated with spa types t186/t325/t786/t1814/t1951, detected in Angola (n = 5) and STP (n = 10); and (ii) PFGE type C-t451/t648-ST8-SCCmec V, exclusively found in STP (n = 9). OS-MRSA showed at least two virulence determinants. PVL was ...Continue Reading

References

Nov 1, 2002·Journal of Clinical Microbiology·Keiko OkumaKeiichi Hiramatsu
Dec 4, 2002·The Journal of Antimicrobial Chemotherapy·E PetinakiA N Maniatis
Nov 8, 2005·Internal Medicine Journal·C Rayner, W J Munckhof
Feb 23, 2007·Journal of Medical Microbiology·Gurdal YilmazIftihar Koksal
Apr 27, 2007·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yasuko HososakaKeisuke Sunakawa
May 30, 2008·Diagnostic Microbiology and Infectious Disease·Betty A ForbesAdriana E Rosato
Mar 20, 2010·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S BreurecB Garin
May 7, 2011·BMC Microbiology·Adebayo O ShittuUlrich Nübel
Mar 2, 2012·Journal of Clinical Microbiology·Feng-Jui ChenUNKNOWN TSAR Hospitals
Oct 10, 2012·Current Opinion in Microbiology·José R MediavillaBarry N Kreiswirth
Sep 13, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Teresa ConceiçãoMarta Aires-de-Sousa
Oct 15, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F SchaumburgK Becker
Apr 4, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Teresa ConceiçãoMarta Aires-de-Sousa
May 25, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·T ConceiçãoM Aires-de-Sousa

❮ Previous
Next ❯

Citations

Apr 23, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P PhakuF Schaumburg
Aug 25, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·K V OkudaR Berner
Feb 12, 2021·Annals of Clinical Microbiology and Antimicrobials·Nathalia Bibiana TeixeiraMaria de Lourdes Ribeiro de Souza da Cunha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.